Skip to content

Krystal Biotech, Inc. KRYS Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Moderna logo
ModernaMRNA
Biogen logo
BiogenBIIB
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s available for sale securities debt securities current?
Krystal Biotech, Inc. (KRYS) reported available for sale securities debt securities current of $322.09M in Q1 2026.
How has Krystal Biotech, Inc.'s available for sale securities debt securities current changed year-over-year?
Krystal Biotech, Inc.'s available for sale securities debt securities current increased by 4.5% year-over-year, from $308.08M to $322.09M.
What is the long-term trend for Krystal Biotech, Inc.'s available for sale securities debt securities current?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s available for sale securities debt securities current has grown at a 156.4% compound annual growth rate (CAGR), from $2.99M to $331.49M.